December 14th 2020, 4:00pm
More than half of the patients (66.7%) in the Venclexta and Rituxan arm who went on to receive subsequent Venclexta-based treatments experienced a partial response or partial nodal response to the therapy.
December 12th 2020, 7:00pm
Approximately half of the patients with breast cancer who failed anti-nausea or vomiting therapy for chemotherapy-induced nausea/vomiting during their first cycle of treatment failed to avoid the side effect at some point during the next three treatment cycles.
December 12th 2020, 4:00pm
Tesetaxel, a novel agent, with Xeloda contributed to a median progression-free survival of 9.8 months, compared with 6.9 months with Xeloda alone, in patients with metastatic breast cancer.
December 11th 2020, 9:30pm
An increase in gastrointestinal side effects were found with the more effective combination of oral paclitaxel and encequidar; however, new safety evaluations demonstrated that various antiemetics can help treat these effects in patients with metastatic breast cancer.
December 6th 2020, 7:30pm
The benefit observed in patients with Waldenstrom’s macroglobulinemia treated with Imbruvica (ibrutinib) plus Rituxan (rituximab), compared with placebo and Rituxan, focused on survival and response to the treatment, both of which occurred despite prior treatment and genotypes.
December 6th 2020, 7:00pm
Dr. Knight presents findings that suggest financial intervention can improve mortality rate in patients with hematologic malignancy at the 2020 ASH Meeting.
December 5th 2020, 9:33pm
Compared with patients assigned bendamustine with Rituxan, those assigned Venclexta with Rituxan maintained an overall survival benefit, with a five-year OS estimate of 82.1% for the Venclexta with Rituxan group vs. 62.2% for the bendamustine with Rituxan group.
December 5th 2020, 9:07pm
Data suggest that patients with CLL/SLL who achieve confirmed undetectable minimal residual disease following 12 cycles of Imbruvica combined with Venclexta could possibly discontinue and reasonably remain off treatment.
December 5th 2020, 8:00pm
An analysis of the phase 2 study IMbark shows how imetelstat can offer patients with high-risk myelofibrosis multiple clinical benefits, setting the stage for an expanded phase 3 trial.
December 5th 2020, 3:00pm
Five patient advocates, two oncologists and one caregiver were honored during CURE®’s eighth annual MPN Heroes Program.